Esmo 2023 News Today

Updated data from several clinical trials in both endometrial and cervical cancer could signal the emergence of multiple effective treatment options coming down the pike.

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Expert gynecologic oncologists discuss recent progress in treating advanced endometrial and cervical cancers, including epidemiology, risk factors, evaluation, staging, and molecular testing.

Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.

Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.

A phase 2 study evaluated meaningful activity from lifileucel for patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors.

Bradley Monk, MD, shares a preview of an upcoming program exploring advancements in the treatment of endometrial and cervical cancers; the panel will discuss recent clinical trial updates, including data from ESMO 2023, and their potential impact on clinical practice.

Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023.

Expert oncologist Aditya Bardia, MD, shares his excitement for an upcoming program centered on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.

Jemperli plus chemotherapy demonstrated improvement in overall survival compared with Keytruda and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.